Why the Resonance Health (ASX:RHT) share price is shooting 39% higher today

The Resonance Health Limited (ASX: RHT) share price is shooting 39% higher today after the company announced an important FDA clearance.

| More on:
Young doctor raising arms in air with hands in fists celebrating a new development

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Resonance Health Limited (ASX: RHT) share price is shooting the lights out today. This comes after the company announced it has received a 510(k) clearance from the United States Food and Drug Administration (FDA) for its HepaFat-AI software.

At the time of writing, the Resonance Health share price is up 38.7% to 21.5 cents. In comparison, the All Ordinaires Index (ASX: XAO) is up 0.7% to 6,969 points.

What's driving the Resonance Health share price?

The Resonance Health share price is surging today following the company's positive FDA clearance announcement.

According to Resonance Health, the FDA has cleared the pathway for the company to begin commercialisation for its HepaFat-AI technology.

HepaFat-AI is a medical imagining technology that uses artificial intelligence to assess liver fat. The software analyses volumetric liver fat fraction (VLFF), proton density fat fraction (PDFF), and steatosis grade in individuals who suffer from fatty liver disease.

Once screened, a doctor or physician is able to explain the results to the patient which can, in turn, support them in weight loss management. In addition, the report can also evaluate if a person has a suitable liver for becoming a donor.

It is estimated that up to 30% of the world's population suffers from non-alcoholic fatty liver disease (NAFLD). This represents up to 2.3 billion people who face the possible risk of developing liver damage and fibrosis.

In financial terms, Resonance reported that over the next 10 years, the increasing incidence of NAFLD could cost the healthcare system $1 trillion in the United States alone. Furthermore, another 334 billion euros could expected to be sunk into treating the disease across Germany, France, Italy and the United Kingdom.

The company said that while there are currently a number of ways to measure liver fat, comparing results from different scan types is very difficult, with results highly variable. HepaFat-AI aims to improve on traditional testing measures by delivering a standardised assessment that allows for accurate comparisons across various scanner types. The company also highlighted that steatosis grading can be time consuming using other methods, however its software has automated the process, allowing for results to be produced much faster.

Resonance Health stated that it intends to pursue multiple channels to get HepaFat-AI to market.

What did management say?

Resonance Health CEO Ms Alison Laws commented on HepaFat-AI's applications and the result from the FDA. She said:

The use of artificial intelligence in medical image review and assessment has the ability to support and transform radiology via the delivery of rapid, reproducible results whenever needed. HepaFat-AI, the Company's second AI-based medical device to gain clearance from the FDA, will enable radiologists to report three key parameters (VLFF, PDFF, and steatosis grade) in patients in this significant and ever-increasing addressable market.

The clearance from the FDA to assess and report all three metrics in HepaFat-AI patient reports is an outstanding result for the Company and an outstanding result for the product itself.

Resonance Health share price summary

The Resonance Health share price has been on the rise since late September, delivering more than a 50% gain to shareholders. Resonance shares are, however, still 17% lower since the beginning of the year.

The Resonance share price reached a 52-week high of 28 cents in January and a 52-week low of 9.2 cents in March.

Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Resonance Health Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why HMC Capital, Platinum, Sigma, and Skycity shares are dropping today

These shares are having a tough session on Tuesday. But why?

Read more »

A close-up photo of a ballot box with an Australian flag in front of it and a gentleman's hands placing his vote in the 2022 election inside the box
Share Market News

How these ASX 200 stocks are primed to gain from Labor's resounding Federal election win

With the Federal election in the rear-view, which ASX 200 stocks should I buy now?

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Share Gainers

Why Dimerix, Evolution Mining, Inghams, and NextDC shares are charging higher today

These shares are rising when many are falling today. But why?

Read more »

Smiling young woman eating chocolate outdoors.
Share Market News

The See's Candies playbook for ASX investors

Two ASX businesses that remind me of Buffett’s sweetest investment.

Read more »

Man smiling at a laptop because of a rising share price.
Opinions

My 2 favourite ASX sectors to invest in

Finding your groove can help your investing success.

Read more »

Legendary share market investing expert and owner of Berkshire Hathaway Warren Buffett
Opinions

3 things I learned from Warren Buffett being the CEO of Berkshire Hathaway

The Oracle from Omaha is in his last year as CEO.

Read more »

A male ASX 200 broker wearing a blue shirt and black tie holds one hand to his chin with the other arm crossed across his body as he watches stock prices on a digital screen while deep in thought
Share Market News

5 things to watch on the ASX 200 on Tuesday

Here's what to expect on the local market today.

Read more »

A neon sign says 'Top Ten'.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a rough trading day for ASX stocks this Monday.

Read more »